Browse by Poster Presenter

Type here to filter the list

H
Hübschmann, Daniel

Computational Oncology, Molecular Precision Oncology Program, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Daniel Hübschmann
Favorite
Hüllein, Jennifer

Computational Oncology, Molecular Precision Oncology Program, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Jennifer Hüllein
Favorite
Haase, Douglas

Kansas University Medical Center
(P 303) SMALLER SARCOMAS AT HIGHER RISK FOR POSITIVE SURGICAL MARGINS: A PARADOX OF PROGNOSTIC FACTORS
Douglas Haase
Favorite
Haas, Rick

NKI-AvL
(P 230) CHARACTERIZING TISSUE-BASED CHANGES DURING AND AFTER RADIOTHERAPY IN MYXOID LIPOSARCOMAS IN THE DOREMY TRIAL
Rick Haas
Favorite
Haddadin, Shadi

Jefferson City Medical Group
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Shadi Haddadin
Favorite
Haddag-Miliani, Leila

INSTITUT GUSTAVE ROUSSY
(P 217) PLANNED MARGINAL (R1) RESECTION IN PRIMARY RETROPERITONEAL SARCOMAS: RETROSPECTIVE SERIES ON 168 PATIENTS FROM A NATIONAL SPECIALIZED REFERRAL CENTER
Leila Haddag-Miliani
Favorite
Haddock, Michael

Mayo Clinic
(P 020) DEFINITIVE RADIATION THERAPY FOR EWING SARCOMA: TREATMENT AND TOXICITY OUTCOMES IN PATIENTS TREATED WITH DOSE ESCALATION APPROACHES
Michael Haddock
Favorite
(P 207) SPATIALLY FRACTIONATED RADIATION THERAPY IN SARCOMAS: THE MAYO CLINIC EXPERIENCE
Michael Haddock
Favorite
Haddox, Candace

Dana-Farber Cancer Institute
(P 143) A PHASE 1 B LEAD-IN TO A RANDOMIZED PHASE 2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA (LMS): RESULTS FROM THE PHASE 1B SOFT-TISSUE SARCOMA (STS) LEAD-IN
Candace Haddox
Favorite
Haefliger, Simon

University College London, Cancer Institute
(P 011) TACKLE A RARE SARCOMA THROUGH A COLLABORATIVE APPROACH
Simon Haefliger
Favorite
Hafez, Navid

Yale Comprehensive Cancer Center, Yale School of Medicine
(P 163) PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MURINE DOUBLE MINUTE 2–TUMOR PROTEIN 53 ANTAGONIST BI 907828 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED SOLID TUMORS
Navid Hafez
Favorite
Haglund de Flon, Felix

Karolinska University Hospital
(P 024) GENETIC REARRANGEMENTS IN 12Q-AMPLIFIED OSTEOSARCOMA RESULT IN ECTOPIC GENE EXPRESSION THROUGH TRANSPOSITION OF REGULATORY ELEMENTS AND SELECTIVE AMPLIFICATION
Felix Haglund de Flon
Favorite
Hagopian, Anahis

UCLA
(P 015) A SIGNAL FINDING STUDY OF NIVOLUMAB AND RELATLIMAB IN ADVANCED CHORDOMA
Anahis Hagopian
Favorite
Hahn, Ezra

Division of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada
(P 290) OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
Ezra Hahn
Favorite
Hakim, Rossella

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit IRCCS Istituto Ortopedico Rizzoli, Bologna
(P 031) PAZOPANIB IN ADVANCED BONE SARCOMA: A RETROSPECTIVE ANALYSIS OF RIZZOLI ORTHOPEDIC INSTITUTE
Rossella Hakim
Favorite
Haller, Florian

Institute of Pathology, University Hospital Erlangen
(P 182) NOVEL TISSUE MICROARRAY (TMA) PLATFORM AS A TOOL FOR COLLABORATIVE SOFT TISSUE SARCOMA (STS) RESEARCH
Florian Haller
Favorite
Halsey, Jordan

Johns Hopkins All Children's Hospital
(P 305) THE INCIDENCE OF THROMBOEMBOLIC EVENTS DURING HOSPITALIZATIONS FOLLOWING SURGICAL RESECTION OF LOWER EXTREMITY SARCOMAS IN CHILDREN: UTILIZING THE PEDIATRIC HEALTH INFORMATION SYSTEM (PHIS) DATABASE
Jordan Halsey
Favorite
Hamacher, Rainer

Department of Medical Oncology, West German Cancer Center, University Hospital Essen
(P 108) NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY
Rainer Hamacher
Favorite
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Rainer Hamacher
Favorite
Hamad, Christopher

University of California, Los Angeles
(P 286) INDICATIONS AND LONGEVITY OF ENDOPROSTHETIC RECONSTRUCTIONS FOR PATIENTS WITH METASTATIC BONE DISEASE
Christopher Hamad
Favorite
Han, ilkyu

Seoul National University School of Medicine
(P 274) AMPUTATION IN PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA: THE EXPERIENCE OF AN EAST ASIAN REFERRAL CENTER
ilkyu Han
Favorite
Han, Jichang

Washington University
(P 139) T-CELL PROFILING IN HIGH GRADE SARCOMAS
Jichang Han
Favorite
Hankins, Margaret

University of Pittsburgh Medical Center
(P 025) INCREASED ALDH1A1 AND ATOX1 GENE EXPRESSION AND COPPER LEVELS IN CANINE OSTEOSARCOMA PATIENTS
Margaret Hankins
Favorite
Han, Mingqi

UCLA Health
(P 173) DYSREGULATION OF MITOCHONDRIAL DYNAMICS IN WELL-DIFFERENTIATED/DEDIFFERENTIATED LIPOSARCOMA PROVIDES A UNIQUE SUSCEPTABILITY TO NOVEL THERAPY
Mingqi Han
Favorite
Hannay, Jonathan

The Royal Marsden Hospital
(P 085) RADIATION ASSOCIATED ANGIOSARCOMAS OF THE BREAST: MULTIFOCALITY WARRANTS AGGRESSIVE ONCOLOGICAL STRATEGY
Jonathan Hannay
Favorite
Hansén Nord, Karolin

Lund University
(P 014) A PLETHORA OF DISEASE-ASSOCIATED ALTERATIONS IN OSTEOSARCOMA
Karolin Hansén Nord
Favorite
(P 024) GENETIC REARRANGEMENTS IN 12Q-AMPLIFIED OSTEOSARCOMA RESULT IN ECTOPIC GENE EXPRESSION THROUGH TRANSPOSITION OF REGULATORY ELEMENTS AND SELECTIVE AMPLIFICATION
Karolin Hansén Nord
Favorite
Han, Yoon Dae

Yonsei University College of Medicine
(P 265) DEVELOPMENT OF THERAPEUTIC STRATEGY FOR DESMOID TUMOR WITH NOVEL PATIENT-DERIVED PRECLINICAL MODEL
Yoon Dae Han
Favorite
Harada, Garrett

Department of Radiation Oncology, University of California Irvine
(P 199) A STUDY OF PRE- AND POST-TREATMENT NEUTROPHIL COUNTS, LYMPHOCYTE COUNTS, AND NEUTROPHIL-TO-LYMPHOCYTE RATIOS IN PATIENTS WITH SOFT TISSUE SARCOMA UNDERGOING RADIOTHERAPY
Garrett Harada
Favorite
Hardes, Jendrik

Clinic of Orthopedics, University Hospital Essen, West German Cancer Centre, Germany
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Jendrik Hardes
Favorite
Hargreaves, Steven

Francis Crick Institute
(P 252) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Steven Hargreaves
Favorite
Harmsen, William

Mayo Clinic
(P 020) DEFINITIVE RADIATION THERAPY FOR EWING SARCOMA: TREATMENT AND TOXICITY OUTCOMES IN PATIENTS TREATED WITH DOSE ESCALATION APPROACHES
William Harmsen
Favorite
(P 201) LOCAL CONTROL AND SURVIVAL OUTCOMES IN PEDIATRIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
William Harmsen
Favorite
Harris, Jeremy

Department of Radiation Oncology, University of California Irvine
(P 199) A STUDY OF PRE- AND POST-TREATMENT NEUTROPHIL COUNTS, LYMPHOCYTE COUNTS, AND NEUTROPHIL-TO-LYMPHOCYTE RATIOS IN PATIENTS WITH SOFT TISSUE SARCOMA UNDERGOING RADIOTHERAPY
Jeremy Harris
Favorite
Hartmann, Wolfgang

University Hospital Muenster, West German Cancer Center Network, Gerhard Domagk Institute for Pathology, Münster, Germany
(P 040) TWO RARE SIDES OF ONE RARE DISEASE: EWING SARCOMA WITH AND AS SECONDARY MALIGNANCIES FROM THE EPIDEMIOLOGICAL AND CLINICAL ANALYSIS OF AN INTERNATIONAL TRIAL REGISTRY
Wolfgang Hartmann
Favorite
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Wolfgang Hartmann
Favorite
Hartner, Lee

Abramson Cancer Center at Pennsylvania Hospital
(P 312) A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Lee Hartner
Favorite
(P 317) INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
Lee Hartner
Favorite
Hauser, Peter

Velkey László Child’s, Health Center, Borsod-Abaúj-Zemplén County University Teaching Hospital
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Peter Hauser
Favorite
Haveman, Lianne

Prinses Máxima Centrum voor Kinderoncologie, Pediatric Oncology, Utrecht, Netherlands
(P 040) TWO RARE SIDES OF ONE RARE DISEASE: EWING SARCOMA WITH AND AS SECONDARY MALIGNANCIES FROM THE EPIDEMIOLOGICAL AND CLINICAL ANALYSIS OF AN INTERNATIONAL TRIAL REGISTRY
Lianne Haveman
Favorite
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Lianne Haveman
Favorite
Hawkins, Douglas

Seattle Children’s Hospital
(P 323) PHASE 2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA.
Douglas Hawkins
Favorite
Hayashi, Masanori

Colorado Children's
(P 237) EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Masanori Hayashi
Favorite
Hayes, Andrew

Royal Marsden Hospital
(P 085) RADIATION ASSOCIATED ANGIOSARCOMAS OF THE BREAST: MULTIFOCALITY WARRANTS AGGRESSIVE ONCOLOGICAL STRATEGY
Andrew Hayes
Favorite
(P 298) PROGNOSIS OF PATIENTS WITH CUTANEOUS ANGIOSARCOMA AFTER SURGICAL RESECTION WITH CURATIVE INTENT: IS THERE A DIFFERENCE BETWEEN THE SUBTYPES?
Andrew Hayes
Favorite
Hays, John

Ohio State University
(P 177) GENOMIC LANDSCAPE OF RARE EWSR1 FUSIONS
John Hays
Favorite
(P 256) TUMOR MUTATIONAL BURDEN AND MICROSATELLITE INSTABILITY IN LEIOMYOSARCOMA
John Hays
Favorite
Heal, Cory

Banner University Medical Center Tucson
(P 208) STEREOTACTIC ABLATIVE BODY RADIOTHERAPY FOR PEDIATRIC OSTEOSARCOMA LUNG METASTASES
Cory Heal
Favorite
Healey, John

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
(P 038) TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT (TOPP): 2-YEAR OBSERVATIONAL SUB-ANALYSIS OF AGE AND PATIENT-REPORTED OUTCOMES FROM AN EU/US PROSPECTIVE REGISTRY
John Healey
Favorite
(P 310) TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
John Healey
Favorite
Healy, Erin

Department of Radiation Oncology, University of California Irvine
(P 199) A STUDY OF PRE- AND POST-TREATMENT NEUTROPHIL COUNTS, LYMPHOCYTE COUNTS, AND NEUTROPHIL-TO-LYMPHOCYTE RATIOS IN PATIENTS WITH SOFT TISSUE SARCOMA UNDERGOING RADIOTHERAPY
Erin Healy
Favorite
Heer, Collin

Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT
(P 178) HIGH FREQUENCY OF NAPRT-SILENCING IN NEUROBLASTOMA AND RHABDOMYSARCOMA CONFERS SENSITIVITY TO TARGETING OF NAD+ METABOLISM USING NAMPT INHIBITORS
Collin Heer
Favorite
Heesen, Philip

University of Zurich
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Philip Heesen
Favorite
(P 072) ESTABLISHING A SARCOMA REFERENCE SCORE FOR EQ-5D
Philip Heesen
Favorite
Heidenreich, Mark

Mayo Clinic
(P 302) SERUM METAL ION CONCENTRATIONS IN THE SETTING OF AN ONCOLOGIC ENDOPROSTHESIS: IS THERE CAUSE FOR CONCERN?
Mark Heidenreich
Favorite
Heilig, Christoph

Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Christoph Heilig
Favorite
Heim, Tanya

University of Pittsburgh Medical Center
(P 046) EVALUATION OF INTRAOPERATIVE TUMOR MARGINS IN SARCOMA WITH FLUORESCENT DYE IMAGING: A PRELIMINARY ANALYSIS OF RESULTS
Tanya Heim
Favorite
Heinrich, Michael

Oregon Health and Science University
(P 096) AN OPEN-LABEL, PHASE 2 EFFICACY STUDY OF TEMOZOLOMIDE IN ADVANCED SUCCINATE DEHYDROGENASE-MUTANT/DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Michael Heinrich
Favorite
(P 121) USING IN VITRO MODELS TO PREDICT IMATINIB RESPONSES IN PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR
Michael Heinrich
Favorite
(P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Michael Heinrich
Favorite
Hemming, Matthew

Dana-Farber Cancer Institute
(P 099) CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Matthew Hemming
Favorite
Henderson, Eric

Dartmouth
(P 071) DEVELOPMENT OF A COLLABORATIVE SARCOMA REGISTRY: STRATEGIES TO DECREASE PROVIDER BURDEN AND INCREASE ENGAGEMENT
Eric Henderson
Favorite
Henning, Jan-Willem

Tom Baker Cancer Centre, University of Calgary
(P 205) PREOPERATIVE CHEMORADIATION (MODIFIED EILBER PROTOCOL) VERSUS NEOADJUVANT/ ADJUVANT RADIOTHERAPY FOR SOFT TISSUE EXTREMITY SARCOMAS: A POPULATION BASED ANALYSIS IN ALBERTA
Jan-Willem Henning
Favorite
HENON, CLEMENCE

INSTITUT GUSTAVE ROUSSY
(P 217) PLANNED MARGINAL (R1) RESECTION IN PRIMARY RETROPERITONEAL SARCOMAS: RETROSPECTIVE SERIES ON 168 PATIENTS FROM A NATIONAL SPECIALIZED REFERRAL CENTER
CLEMENCE HENON
Favorite
Hensley, Martee

Memorial Sloan Kettering Cancer Center
(P 134) PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Martee Hensley
Favorite
Herbsthofer, Laurin

Center for Biomarker Research in Medicine (CBmed)
(P 141) TUMOUR-INFILTRATING IMMUNE CELLS IN SOFT TISSUE SARCOMA. IMPACT ON LOCAL RECURRENCE, DISTANT METASTASIS, AND OVERALL SURVIVAL.
Laurin Herbsthofer
Favorite
Herbst, Leyla

Rush University Medical Center
(P 283) HIP ARTHROPLASTY OUTCOMES IN METASTATIC BONE DISEASE
Leyla Herbst
Favorite
Hernandez, Jose Emilio

HCU VIRGEN ARRIXACA
(P 318) NEOADJUVANT CHEMORADIOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA. UPDATED NASAR STUDY
Jose Emilio Hernandez
Favorite
Hernandez, Sergio

Hospital general universitario gregorio marañon
(P 119) SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Sergio Hernandez
Favorite
Herrmann, Ken

Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Ken Herrmann
Favorite
Hesla, Asle

Karolinska University Hospital
(P 242) LIPOSARCOMAS WITH 12Q AMPLIFICATION - CAN GENETIC CHANGES DISCLOSE THE DEVELOPMENT AND ORIGIN OF RING CHROMOSOMES?
Asle Hesla
Favorite
Heyes, Catriona

RTI Health Solutions
(P 260) BURDEN OF ILLNESS OF DESMOID TUMORS
Catriona Heyes
Favorite
Heyl, Alma

University of Pittsburgh Medical Center
(P 046) EVALUATION OF INTRAOPERATIVE TUMOR MARGINS IN SARCOMA WITH FLUORESCENT DYE IMAGING: A PRELIMINARY ANALYSIS OF RESULTS
Alma Heyl
Favorite
He, Yulong

The Seventh Affiliated Hospital of SunYat-sen University, Shenzhen, 518000
(P 101) CYTOREDUCTIVE SURGERY FOR METASTATIC GASTROINTESTINAL STROMAL TUMORS TREATED WITH RIPRETINIB: A SINGLE-CENTER ANALYSIS.
Yulong He
Favorite
He, Yulong

Gastrointestinal Surgery Center, The First Affiliated Hospital of Sun Yat-sen University
(P 111) PLASMA CONCENTRATION MONITORING AND PERSONALIZED DESENSITIZATION THERAPY IN PATIENTS OF GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB-ASSOCIATED SKIN RASH
Yulong He
Favorite
Hieken, Tina

Mayo Clinic (Rochester)
(P 289) MERKEL CELL CARCINOMA OF UNKNOWN PRIMARY: CLINICAL PRESENTATION AND OUTCOMES
Tina Hieken
Favorite
Hiemenz, Matthew

Foundation Medicine
(P 010) SPECTRUM OF EWING-LIKE FUSIONS AND SECONDARY GENOMIC ALTERATIONS FROM A LARGE NEXT GENERATION SEQUENCING (NGS) COMPREHENSIVE GENOMIC PROFILING (CGP) DATABASE
Matthew Hiemenz
Favorite
Higashi, Takahiro

National Cancer Center Hospital
(P 069) CLINICOPATHOLOGICAL FEATURES AND TREATMENT PATHWAYS OF SOFT TISSUE SARCOMA BY TISSUE OF ORIGIN
Takahiro Higashi
Favorite
Hildebrand, Karys

University of Calgary
(P 128) INVESTIGATING THE ROLE OF MACROPHAGES IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Karys Hildebrand
Favorite
(P 142) USE OF SMALL MOLECULE STIMULATE OF TYPE-1 INTERFERON GENES (STING) AGONIST IMMUNOTHERAPY FOR CANINE SARCOMA: A CROSS-SPECIES ANALYSIS
Karys Hildebrand
Favorite
Hildebrand, Kurt

University of Calgary
(P 128) INVESTIGATING THE ROLE OF MACROPHAGES IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Kurt Hildebrand
Favorite
Hindi, Nadia

Fundacion Jimenez Diaz University Hospital/HG Villalba and Instituto de Investigaciones Sanitarias Fundación Jimenez Diaz
(P 113) PROGNOSTIC AND/OR PREDICTIVE VALUE OF EXON 11 MUTATIONS IN TUMOR RESPONSE TO IMATINIB IN METASTATIC GASTROINTESTINAL STROMAL TUMOR :RETROSPECTIVE ANALYSIS OF A MULTICENTRIC NATIONAL REGISTRY
Nadia Hindi
Favorite
(P 135) PREDICTIVE VALUE OF ISG15 AND PPAP2B IN SOLITARY FIBROUS TUMOR TREATED WITH SUNITINIB AND NIVOLUMAB: A CORRELATIVE STUDY FROM IMMUNOSARC, A SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS) PHASE II TRIAL
Nadia Hindi
Favorite
(P 161) PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
Nadia Hindi
Favorite
(P 204) PERCEPTIONS AND MANAGEMENT PRACTICES OF SARCOMA EXPERTS ABOUT SOFT TISSUE SARCOMA PATIENTS WITH ISOLATED LUNG METASTASES ACROSS EUROPE
Nadia Hindi
Favorite
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Nadia Hindi
Favorite
Hiniker, Susan

Stanford University
(P 155) LATE EVENTS OCCURRING AFTER 5 YEARS IN PEDIATRIC RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Susan Hiniker
Favorite
Hirbe, Angela

Washington University in St. Louis
(P 075) EXAMINING PATIENT PERSPECTIVES ON SARCOMA SURVEILLANCE: THE SARCOMA SURVEILLANCE SURVEY
Angela Hirbe
Favorite
Hirmas, Nader

Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Nader Hirmas
Favorite
Hirsch, Ian

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto; CanSaRCC, Princess Margaret Cancer Centre, Toronto
(P 068) CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Ian Hirsch
Favorite
Hitachi, Shin

Tohoku University School of Medicine
(P 091) THE PROGNOSIS OF PULMONARY METASTASIS AFTER THE SURGERY FOR PRIMARY LESION IN ELDERLY HIGH-GRADE SARCOMA PATIENTS
Shin Hitachi
Favorite
(P 209) THE OUTCOME OF R1 EXCISION COMBINED WITH ADJUVANT RADIOTHERAPY FOR SOFT TISSUE SARCOMA IN ELDERLY PATIENTS
Shin Hitachi
Favorite
Hogdall, Estrid

Department of Pathology, Copenhagen University Hospital, Herlev and Gentofte Hospital
(P 120) THE DIAGNOSTIC AND PROGNOSTIC VALUE OF PLASMA SMALL EXTRACELLULAR VESICLES PHENOTYPE IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOUR
Estrid Hogdall
Favorite
Hohenberger, Peter

Div.of Surgical Oncology and Thoracic surgery, Mannheim University Medical Center, University of Heidelberg, Germany
(P 264) DESMOID AND TRAUMA: REAL INCIDENCE AND MEDICOLEGAL ASPECTS OF CAUSALITY
Peter Hohenberger
Favorite
Hohenberger, Ralph

Dept. of ENT, University Hospital, University of Heidelberg, Germany
(P 264) DESMOID AND TRAUMA: REAL INCIDENCE AND MEDICOLEGAL ASPECTS OF CAUSALITY
Ralph Hohenberger
Favorite
Ho, Jason

Inhibrx, Inc
(P 317) INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
Jason Ho
Favorite
Hokamp, Karsten

Trinity College Dublin, Smurfit Institute
(P 235) ELUCIDATING THE ONCOGENIC EFFECT OF BCOR-ITD IN SARCOMA
Karsten Hokamp
Favorite
Holcomb, Monica

Inhibrx, Inc
(P 317) INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
Monica Holcomb
Favorite
Holloway, Caroline

BC Cancer
(P 165) REAL- WORLD EXPERIENCE OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH RECURRENT BONE TUMOURS (BT): A CANSARCC STUDY
Caroline Holloway
Favorite
Holten, Anna

University of Minnesota
(P 075) EXAMINING PATIENT PERSPECTIVES ON SARCOMA SURVEILLANCE: THE SARCOMA SURVEILLANCE SURVEY
Anna Holten
Favorite
Hompes, Daphne

University Hospitals Gasthuisberg
(P 198) XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Daphne Hompes
Favorite
Hompland, Ivar

Oslo University Hospital
(P 114) PROGNOSTIC IMPACT OF CIRCULATING TUMOR DNA DETECTION IN FIRST-LINE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR
Ivar Hompland
Favorite
Hong, Angela

The University of Sydney
(P 258) TO TREAT OR NOT TO TREAT: AN AUDIT OF INITIAL MANAGEMENT OF PATIENTS WITH DESMOID TUMOURS AT A SPECIALISED CENTRE
Angela Hong
Favorite
Hong, David

The University of Texas MD Anderson Cancer Center
(P 107) LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
David Hong
Favorite
(P 127) IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
David Hong
Favorite
Hong, Zachery

Washington University School of Medicine in St. Louis
(P 075) EXAMINING PATIENT PERSPECTIVES ON SARCOMA SURVEILLANCE: THE SARCOMA SURVEILLANCE SURVEY
Zachery Hong
Favorite
Honoki, Kanya

Nara Medical University
(P 181) MITOCHONDRIAL TRANSFER FROM MESENCHYMAL STEM CELSS MEDIATED BY HMGB1 COULD BE INVOLVED IN DRUG RESISTANCE IN OSTEOSARCOMA CELLS.
Kanya Honoki
Favorite
Honore, Charles

Department of Surgical Oncology, Institut Gustave Roussy
(P 217) PLANNED MARGINAL (R1) RESECTION IN PRIMARY RETROPERITONEAL SARCOMAS: RETROSPECTIVE SERIES ON 168 PATIENTS FROM A NATIONAL SPECIALIZED REFERRAL CENTER
Charles Honore
Favorite
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Charles Honore
Favorite
Hornicek, Francis

University of Miami
(P 015) A SIGNAL FINDING STUDY OF NIVOLUMAB AND RELATLIMAB IN ADVANCED CHORDOMA
Francis Hornicek
Favorite
(P 184) PAN-SARCOMA ORGANOID SCREENING PIPELINE
Francis Hornicek
Favorite
(P 243) MUTATIONAL ANALYSIS OF PRIMARY AND ADVANCED CHORDOMA TISSUE USING NEXT-GENERATION SEQUENCING
Francis Hornicek
Favorite
Hornick, Jason

Brigham and Women’s Hospital
(P 099) CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Jason Hornick
Favorite
(P 167) STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY
Jason Hornick
Favorite
Hoshi, Hisakazu

University of Iowa Hospitals & Clinics
(P 160) NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Hisakazu Hoshi
Favorite
Hosni, Ali

Division of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada
(P 290) OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
Ali Hosni
Favorite
Houdek, Matthew

Mayo Clinic
(P 278) ACUTE CARDIAC CHANGES IN PEDIATRIC AND YOUNG ADULT SOLID TUMOR PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
Matthew Houdek
Favorite
(P 284) HOW DO THE OUTCOMES OF RADIATION ASSOCIATED PELVIC AND SACRAL BONE SARCOMAS COMPARE TO PRIMARY OSTEOSARCOMAS FOLLOWING SURGICAL RESECTION?
Matthew Houdek
Favorite
(P 289) MERKEL CELL CARCINOMA OF UNKNOWN PRIMARY: CLINICAL PRESENTATION AND OUTCOMES
Matthew Houdek
Favorite
(P 291) OUTCOME OF MULTIDISCIPLINARY TREATMENT OF MERKEL CELL CARCINOMA OF THE UPPER EXTREMITY
Matthew Houdek
Favorite
(P 293) OUTCOMES OF MULTIDISCIPLINARY TREATMENT OF MERKEL CELL CARCINOMA OF THE LOWER EXTREMITY
Matthew Houdek
Favorite
(P 296) PET IMAGING VERSUS CLINICAL EXAMINATION IN DETERMINING LYMPH NODE INVOLVEMENT IN MERKEL CELL CARCINOMA OF THE EXTREMITY
Matthew Houdek
Favorite
(P 302) SERUM METAL ION CONCENTRATIONS IN THE SETTING OF AN ONCOLOGIC ENDOPROSTHESIS: IS THERE CAUSE FOR CONCERN?
Matthew Houdek
Favorite
Houtman, Jon

University of Iowa Carver College of Medicine
(P 159) NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Jon Houtman
Favorite
(P 160) NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Jon Houtman
Favorite
Ho, Vincent

Integraal kankercentrum Nederland (IKNL)
(P 103) GIST PATIENT AND TUMOR CHARACTERISTICS IN REFERENCE CENTERS AND NON-REFERENCE CENTERS: DATA FROM A NATIONWIDE REGISTRY
Vincent Ho
Favorite
Hsu, Chia-Wei

St. Jude Children's Research Hospital
(P 012) ACUTE CARDIAC CHANGES IN PEDIATRIC AND YOUNG ADULT SOLID TUMOR PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
Chia-Wei Hsu
Favorite
Hsu, David

Department of Medicine, Duke Cancer Institute, Duke University
(P 171) CANINE-DERIVED OSTEOSARCOMA ORGANOIDS MODEL TUMOR HETEROGENEITY AND CHEMOTHERAPY RESISTANCE
David Hsu
Favorite
Huang, Alex

Case Western Reserve University School of Medicine
(P 310) TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
Alex Huang
Favorite
Huang, Jie

Eisai Inc.
(P 043) A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Jie Huang
Favorite
Huang, Liyue

Vigil Neuroscience
(P 187) PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA
Liyue Huang
Favorite
Huang, Paul

The Institute for Cancer Research
(P 061) UNRAVELLING THE HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT IN STS USING QUANTITATIVE MRI
Paul Huang
Favorite
(P 152) FINAL RESULTS OF GEMMK: A PHASE I TRIAL OF GEMCITABINE AND PEMBROLIZUMAB IN PATIENTS WITH LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Paul Huang
Favorite
(P 188) PRELIMINARY ASSESSMENT OF CIRCULATING INFLAMMATORY CYTOKINES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) PATIENTS AND IN AN EHE PATIENT-DERIVED XENOGRAFT BEFORE AND AFTER DOXORUBICIN AND SIROLIMUS
Paul Huang
Favorite
Huang, Zhen

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，100021
(P 097) COMBINATION THERAPY OF TYROSINE KINASE INHIBITORS WITH RIPRETINIB AS THERAPEUTIC EXPLORATION FOR REFRACTORY GASTROINTESTINAL STROMAL TUMORS AFTER PROGRESSION FROM STANDARD THERAPY: A CASE REPORT
Zhen Huang
Favorite
Huebner, Dirk

Cogent Biosciences
(P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Dirk Huebner
Favorite
Hughes, Jim

The Life Raft Group
(P 110) PHASE I RESULTS FROM A MULTI-PHASE COMPREHENSIVE GENOMIC SEQUENCING TUMOR STUDY IN GASTROINTESTINAL STROMAL TUMOR PATIENTS
Jim Hughes
Favorite
Hu, Haiyan

Shanghai Sixth People's Hospital
(P 136) PRELIMINARY EFFICACY AND SAFETY OF FAMITINIB PLUS SHR-1701 IN ADVANCED SARCOMA: A SINGLE-CENTER, PHASE 2 TRIAL
Haiyan Hu
Favorite
Huh, Winston

Children's Hospital Los Angeles
(P 045) DETECTION OF CELL-FREE TUMOR DNA IN PATIENTS WITH NEWLY DIAGNOSED PEDIATRIC BONE AND SOFT TISSUE SARCOMAS
Winston Huh
Favorite
(P 151) CLINICAL PRESENTATION OF OSTEOSARCOMA PATIENTS WITH ACUTE METHOTREXATE TOXICITY TREATED WITH GLUCARPIDASE
Winston Huh
Favorite
Huis in 't Veld, Eva

Erasmus Medical Center
(P 298) PROGNOSIS OF PATIENTS WITH CUTANEOUS ANGIOSARCOMA AFTER SURGICAL RESECTION WITH CURATIVE INTENT: IS THERE A DIFFERENCE BETWEEN THE SUBTYPES?
Eva Huis in 't Veld
Favorite
Hui, Wun Chun

The Chinese University of Hong Kong
(P 186) PRECLINICAL STUDY OF DOXORUBICIN IN COMBINATION WITH PANOBINOSTAT IN XENOGRAFT MICE MODELS OF SOFT TISSUE SARCOMAS
Wun Chun Hui
Favorite
Hung, Giun-Yi

Taipei Veterans General Hospital
(P 043) A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Giun-Yi Hung
Favorite
Hurh, Eunju

C4 Therapeutics
(P 312) A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Eunju Hurh
Favorite
Hussein, Maen

Florida Cancer Specialists North Division
(P 313) A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
Maen Hussein
Favorite
Husson, Olga

Netherlands Cancer Institute
(P 115) PSYCHOLOGICAL AND SOCIAL CHALLENGES OF PATIENTS WITH ADVANCED AND METASTATIC GASTROINTESTINAL STROMAL TUMORS ON LONG-TERM TREATMENT WITH TYROSINE KINASE INHIBITORS: A QUALITATIVE STUDY
Olga Husson
Favorite
(P 272) PREGNANCY-ASSOCIATED DESMOID FIBROMATOSIS: A DUTCH MULTI-CENTRE RETROSPECTIVE ANALYSIS
Olga Husson
Favorite
(P 319) PATIENT REPORTED OUTCOME ASSESSMENT AND REPORTING IN RANDOMIZED CLINICAL TRIALS OF SYSTEMIC THERAPY FOR ADVANCED SOFT TISSUE SARCOMAS; PROTOCOL FOR A SYSTEMATIC REVIEW
Olga Husson
Favorite
Hwang, Gloria

Stanford University
(P 130) MONITORING SOFT TISSUE SARCOMA RESPONSE TO IMMUNE CHECKPOINT INHIBITION AND CRYOTHERAPY WITH CIRCULATING TUMOR DNA ANALYSIS
Gloria Hwang
Favorite